Pharmaceuticals - Indian - Formulations
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 644.42 | 523.05 | 472.64 | 430.69 | 331.34 |
Total Expenses | 567.33 | 466.01 | 427.07 | 387.17 | 299.20 |
Profit Before Tax | 77.09 | 57.04 | 45.56 | 21.74 | 24.67 |
Profit After Tax | 58.19 | 42.63 | 38.09 | 15.57 | 16.21 |
Operating Profit after Depreciation | 78.20 | 57.83 | 46.98 | 44.82 | 34.66 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 179.05 | 110.38 | 91.62 | 95.94 | 70.26 |
Total Non Current Assets | 194.92 | 175.44 | 109.36 | 101.81 | 170.46 |
Total Current Assets | 431.29 | 353.54 | 381.65 | 194.31 | 168.03 |
TOTAL ASSETS | 626.21 | 528.98 | 491.01 | 296.12 | 338.49 |
Total Shareholder's Fund | 449.94 | 402.27 | 394.78 | 199.12 | 209.66 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 108.96 | 60.97 | 9.13 | 11.46 | 25.01 |
Net Cash used in Investing Activities | -92.07 | -14.11 | -154.58 | -20.20 | -14.34 |
Net Cash used in Financing Activities | -15.29 | -43.74 | 130.09 | 0.78 | -5.44 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 644.42 | 523.05 | 472.64 | 430.70 | 329.81 |
Total Expenses | 567.40 | 465.99 | 426.60 | 387.17 | 299.24 |
Profit Before Tax | 77.02 | 57.06 | 46.04 | 11.18 | 30.57 |
Profit After Tax | 58.14 | 42.64 | 38.56 | 5.01 | 22.46 |
Operating Profit after Depreciation | 78.13 | 57.84 | 47.45 | 44.82 | 32.94 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 179.05 | 110.38 | 91.62 | 95.94 | 68.43 |
Total Non Current Assets | 194.92 | 175.47 | 109.39 | 101.85 | 181.14 |
Total Current Assets | 431.24 | 353.54 | 381.63 | 194.15 | 162.66 |
TOTAL ASSETS | 626.16 | 529.01 | 491.03 | 295.99 | 343.80 |
Total Shareholder's Fund | 450.29 | 402.67 | 395.13 | 198.99 | 216.48 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 108.91 | 60.98 | 9 | 11.45 | 20.87 |
Net Cash used in Investing Activities | -92.07 | -14.11 | -154.31 | -20.19 | -9.16 |
Net Cash used in Financing Activities | -15.29 | -43.74 | 130.09 | 0.78 | -6.48 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 187 | 175.15 | 171.29 | 162.21 | 152.67 |
Total Expenses | 163.95 | 154.27 | 149.28 | 141.88 | 133.99 |
Profit Before Tax | 20.29 | 18.31 | 22.63 | 19.79 | 18.30 |
Profit After Tax | 15.66 | 13.48 | 16.99 | 15.10 | 14.03 |
Operating Profit after Depreciation | 27.89 | 25.01 | 26.45 | 23.49 | 21.92 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 187 | 175.15 | 171.29 | 162.21 | 152.67 |
Total Expenses | 163.95 | 154.27 | 149.35 | 141.88 | 133.99 |
Profit Before Tax | 20.29 | 18.31 | 22.56 | 19.79 | 18.30 |
Profit After Tax | 15.66 | 13.48 | 16.95 | 15.10 | 14.03 |
Operating Profit after Depreciation | 27.89 | 25.01 | 26.38 | 23.49 | 21.92 |
₹5.5/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Windlas Biotech Ltd | ₹1,000.65 | ₹2,091.39 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
10 Jan 2025, 03:42 pm
10 Jan 2025, 01:05 pm
03 Jan 2025, 08:23 pm
06 Nov 2024, 01:51 pm
03 Sep 2024, 05:28 pm